- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02697318
Evaluation of a New Method for Instilling Eye Drops
The purpose of this project is to demonstrate that there is a new easier method to instill eye drops in ones own eye that is as effective as applying a drop directly to their open eye. The benefits of this new method include better medication compliance and reduced patient anxiety from instilling their eye drops. This secondary benefit should remove the "approach-avoidance response" that prompts some patients to delay or give-up on instilling their drops just to avoid the angst and frustration produced by the challenge.
The new method involves the patient instilling the eye drop onto their closed eyelid and then blinking the eye drop into their eye. We aim to show that this method has a similar therapeutic effect as the routine administration of an eye drop to an open eye.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PURPOSE:
The purpose of this project is to test an alternative method for instilling eye drops. The new method involves the patient self-administer the eye drop onto the skin of their medial canthus, with the lids gently closed, and then open the lids once the "cold and wet" sensation of the eye drop is felt along the margins of the closed lids. We will compare the physiological and therapeutic efficacy of instilling the same eye drops into the eyes of the same subjects, using two methods. The first will be to have the eye drop administered using the "gold standard" method employed by optometrists to instill eye drops in the office. The second will be to employ the new method of self-administration described above.
HYPOTHESIS:
Instillation of an eye drop, over the gently closed lids at the medial canthus, has the same physiological effect and therapeutic efficacy as a drop of the same agent, at the same concentration, properly applied onto an open eye by a trained professional.
Aim #1: Determine if there is a difference in efficacy between drops of 0.5% timolol maleate administered by a professional, using the standard clinical method versus patient self-administration using the newly proposed method, in NORMAL SUBJECTS.
Aim #2: Determine if there is a difference in efficacy between glaucoma drops administered by a professional, using the standard method versus with patient self-administration of the same drop, using the newly proposed method, in GLAUCOMA PATIENTS.
JUSTIFICATION:
While new drug development in the glaucoma field seeks to address the issue of the difficulty patients experience with self-administration of an eye drop by pressing for new drugs that show efficacy in a once daily dosing routine, this strategy has potentially serious negative consequences. Clearly, when glaucoma medications are administered only once a day, if the patient misses their eye on that single instillation, the period of lapsed treatment is 24 hours or more. If their disease worsens, either due to non-compliance with their treatment regimen or inability to instill an eye drop, they will require more follow up visits, additional medications, additional diagnostic tests, and earlier surgery.
In this regard, the consequences of non-compliance or inability to comply are the same - increased blindness from glaucoma and increased costs associated with trying to prevent this blindness in needlessly advancing disease.
OBJECTIVES:
The objective of this proposal is to test the therapeutic efficacy of an alternative method of instilling eye drops. This requires comparing the effects of the same volume of the same drug, applied using the classical method and the new alternative method. If the proposed study is successful, a more reliable method for instilling drops of all kinds, to all patients, will have been validated.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Waterloo, Ontario, Canada, N2L3G1
- University of Waterloo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Aim #1:
Inclusion Criteria:
- both male and female participants are being studied
- minimum age of 21 and maximum age of 80
- healthy volunteers with no previous history of eye disease
Exclusion Criteria:
- no medical conditions representing contraindications to use of topical beta-blocker.
- subject must not have any active inflammatory diseases of the eye, or have a diagnosis of any form of glaucoma
Aim #2:
Inclusion Criteria:
- both male and female participants are being studied
- minimum age of 21 and maximum age of 80
- subjects have been diagnosed with primary open angle glaucoma and are stable on monotherapy
Exclusion Criteria:
- Subjects must have no other ocular disease, or a history of prior ocular trauma, beyond minor corneal abrasion or removal of a superficial corneal foreign body.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Professional Administration
Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) administered by a professional, using the standard clinical method.
|
|
OTHER: Self-Administration (new method)
Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) self-administered by the participant, using the new proposed method.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraocular Pressure
Time Frame: 2 hours
|
Intraocular Pressure by Goldmann applanation will be measured pre- and 2 hours post timolol maleate 0.5% ophthalmic solution
|
2 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Ocular Hypertension
- Glaucoma
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Pharmaceutical Solutions
- Timolol
- Ophthalmic Solutions
Other Study ID Numbers
- 21282
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Bausch & Lomb IncorporatedNicOx Inc.CompletedPrimary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaFrance
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Wills EyeOptovueCompletedPrimary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma; DrugsUnited States
-
University of California, San FranciscoUniversity of Colorado, Denver; University of Maryland; Zhongshan Ophthalmic... and other collaboratorsCompletedPrimary Open Angle Glaucoma | Glaucoma | Neovascular Glaucoma | Secondary GlaucomaUnited States, China, India, Mexico
Clinical Trials on Timolol maleate 0.5% ophthalmic solution
-
Alcon ResearchCompletedOcular Hypertension | Open-angle GlaucomaUnited States
-
Alcon ResearchCompletedOcular Hypertension | Open-angle Glaucoma
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open-angle Glaucoma
-
Aerie PharmaceuticalsCompleted
-
Santen Inc.Completed
-
Alcon ResearchCompletedOcular Hypertension | Glaucoma, Open-angleBelgium
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle Glaucoma
-
Qlaris Bio, Inc.CompletedNormal Tension Glaucoma (NTG)United States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open-angle GlaucomaUnited States